HRP20230632T1 - Gla domene kao terapijska sredstva - Google Patents
Gla domene kao terapijska sredstva Download PDFInfo
- Publication number
- HRP20230632T1 HRP20230632T1 HRP20230632TT HRP20230632T HRP20230632T1 HR P20230632 T1 HRP20230632 T1 HR P20230632T1 HR P20230632T T HRP20230632T T HR P20230632TT HR P20230632 T HRP20230632 T HR P20230632T HR P20230632 T1 HRP20230632 T1 HR P20230632T1
- Authority
- HR
- Croatia
- Prior art keywords
- virus
- polypeptide according
- polypeptide
- treatment
- disease
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 229940096437 Protein S Drugs 0.000 claims 2
- 102000029301 Protein S Human genes 0.000 claims 2
- 108010066124 Protein S Proteins 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003253 Arthritis enteropathic Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 206010003274 Arthritis viral Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000000280 Cyclic neutropenia Diseases 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 206010018498 Goitre Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 241000150562 Hantaan orthohantavirus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 206010020608 Hypercoagulation Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000150452 Orthohantavirus Species 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000003872 goiter Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000003027 hypercoagulation Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
Claims (15)
1. Proba i/ili terapeutski polipeptid prikladan za ciljanje ekspresije fosfatidilserina na površini stanice i in vitro i in vivo navedeni polipeptid koji sadrži:
domena proteina S gama-karboksiglutaminske kiseline (Gla), i
EGF domena,
pri čemu je navedeni polipeptid fuzioniran na proteinsku sekvencu; i
pri čemu navedenom polipeptidu nedostaje domena proteaze i također nedostaje domena za vezanje hormona.
2. Polipeptid prema zahtjevu 1, naznačen time što sadrži EGF domenu iz proteina S.
3. Polipeptid prema zahtjevu 2, naznačen time, da GLA domena ima sekvencu prikazanu u SEQ ID NO: 1.
4. Polipeptid prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se polipeptid sastoji od 300 aminokiselina ili manje.
5. Polipeptid prema bilo kojem od zahtjeva 1 do 3, naznačen time što sadrži SEQ ID NO: 6.
6. Polipeptid prema bilo kojem od zahtjeva 1 do 5, naznačen time, da polipeptid dalje sadrži antitijelo Fc regija.
7. Polipeptid prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se koristi u liječenju.
8. Polipeptid prema zahtjevu 7, naznačen time, da se koristi u liječenju u kombiniranoj terapiji.
9. Polipeptid prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se koristi u liječenju raka.
10. Polipeptid prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se koristi u liječenju virusne infekcije.
11. Polipeptid prema zahtjevu 10, naznačen time, da se koristi u liječenju virusne infekcije odabrane iz skupine koju čine gripe, virusa humane imunodeficijencije, virusa denge, virusa zapadnog Nila, virusa velikih boginja, respiratornog sincicijalni virus, virus korejske hemoragijske groznice, vodene kozice, virus varicella zoster, herpes simplex virus 1 ili 2, Epstein-Barr virus, Marburg virus, hantavirus, virus žute groznice, hepatitis A, B, C ili E, virus ebole, humani papiloma virus, rinovirus, Coxsackie virus, polio virus, virus ospica, virus rubeole, virus bjesnoće, virus newcastleske bolesti, rotavirus, HTLV-1 i -2.
12. Polipeptid prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se koristi u liječenju poremećaja hiperkoagulacije.
13. Polipeptid prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se koristi u liječenju autoimunih i/ili upalnih bolesnih stanja.
14. Polipeptid za upotrebu prema zahtjevu 13, naznačen time što je bolesno stanje odabrano iz skupine koja se sastoji od spondiloartropatija, ankilozantni spondilitis, psorijatični artritis, reaktivni artritis, enteropatski artritis, ulcerozni kolitis, Crohnova bolest, bolest iritabilnog crijeva, upalna bolest crijeva, reumatoidni artritis, juvenilni reumatoidni artritis, obiteljska mediteranska groznica, amiotrofična lateralna skleroza, Sjogren' s sindrom, rani artritis, virusno artritis, multipla skleroza, sistemski eritematozni lupus, psorijaza, vaskulitis, Wegenerova granulomatoza, Addisonova bolest, alopecija, antifosfolipidni sindrom, Behcetova bolest, celijakija, sindrom kroničnog umora, ulcerozni kolitis, dijabetes tipa I, fibromijalgija, autoimuni gastritis, Goodpastureov sindrom , Gušavost, idiopatska trombocitopenična purpura (ITP), miastenija gravis, pemfigus vulgaris, primarna bilijarna ciroza, reumatska groznica, sarkoidoza, sklerodermija, vitiligo, vaskulitis, vaskulitis malih krvnih žila, hepatitis, primarna bilijarna ciroza, sarkoidoza, sklerodermija, reakcija presatka protiv domaćina (akutna i kronična), aplastična anemija i ciklička neutropenija.
15. Polipeptid prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se koristi u liječenju sepse.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361787753P | 2013-03-15 | 2013-03-15 | |
US201361791537P | 2013-03-15 | 2013-03-15 | |
EP19160280.4A EP3524617B1 (en) | 2013-03-15 | 2014-03-13 | Gla domains as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230632T1 true HRP20230632T1 (hr) | 2023-09-29 |
Family
ID=51580982
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230632TT HRP20230632T1 (hr) | 2013-03-15 | 2014-03-13 | Gla domene kao terapijska sredstva |
HRP20230527TT HRP20230527T1 (hr) | 2013-03-15 | 2014-03-13 | Gla domene kao ciljni agensi |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230527TT HRP20230527T1 (hr) | 2013-03-15 | 2014-03-13 | Gla domene kao ciljni agensi |
Country Status (25)
Country | Link |
---|---|
US (6) | US10894075B2 (hr) |
EP (5) | EP2970442B1 (hr) |
JP (4) | JP6595977B2 (hr) |
CN (2) | CN105164152B (hr) |
AU (2) | AU2014233885B2 (hr) |
BR (2) | BR112015021866A2 (hr) |
CA (3) | CA2905986A1 (hr) |
CY (2) | CY1126074T1 (hr) |
DK (4) | DK3524617T3 (hr) |
ES (4) | ES2756532T3 (hr) |
FI (2) | FI3524617T3 (hr) |
HK (2) | HK1215263A1 (hr) |
HR (2) | HRP20230632T1 (hr) |
HU (2) | HUE062055T2 (hr) |
IL (3) | IL240530B (hr) |
MX (3) | MX2015011409A (hr) |
MY (2) | MY176901A (hr) |
PE (2) | PE20152020A1 (hr) |
PL (3) | PL3524617T3 (hr) |
PT (2) | PT3524617T (hr) |
RU (3) | RU2705786C2 (hr) |
SA (1) | SA515361061B1 (hr) |
SG (3) | SG11201506880WA (hr) |
WO (2) | WO2014151683A1 (hr) |
ZA (2) | ZA201507670B (hr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2756532T3 (es) * | 2013-03-15 | 2020-04-27 | Gladiator Biosciences Inc | Dominios de Gla como agentes de direccionamiento |
WO2015170778A1 (ja) * | 2014-05-08 | 2015-11-12 | 学校法人日本大学 | ホスファチジルセリンの細胞表面への表出促進剤又は表出抑制剤、及び脂質ラフトのクラスター形成抑制剤 |
CN104745649B (zh) * | 2015-02-28 | 2018-03-09 | 苏州汉酶生物技术有限公司 | 一种福沙那韦中间体的生物制备方法 |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
US11820833B2 (en) * | 2016-06-05 | 2023-11-21 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Peptides that inhibit binding of EPCR to its ligand to treat inflammation |
US11352404B2 (en) | 2017-07-24 | 2022-06-07 | Rutgers, The State University Of New Jersey | Phosphatidylserine targeting fusion molecules and methods for their use |
CN111051500A (zh) * | 2017-09-05 | 2020-04-21 | 角斗士生物科学公司 | 有效载荷递送至干细胞 |
CN108159421B (zh) * | 2018-02-05 | 2021-05-18 | 苏州大学 | 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途 |
JP2021514402A (ja) * | 2018-02-20 | 2021-06-10 | プロミネント メディカル インコーポレイテッドProminent Medical Inc. | 酸化アルミニウム表面及び界面分子 |
CA3177374A1 (en) * | 2018-10-22 | 2020-04-30 | Asahi Kasei Pharma Corporation | Medicament for therapeutic treatment and/or improvement of sepsis accompanied by coagulopathy |
CN113061169B (zh) * | 2020-03-24 | 2022-09-27 | 江南大学 | 一种转录调控蛋白及其在共轭亚油酸生产中的应用 |
CN112057623A (zh) * | 2020-06-03 | 2020-12-11 | 江苏靶标生物医药研究所有限公司 | 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用 |
RU2768194C1 (ru) * | 2021-08-02 | 2022-03-23 | федеральное государственное бюджетное образовательное учреждение высшего образования "Нижегородский государственный технический университет им. Р.Е. Алексеева" (НГТУ) | Способ оценки степени экстернализации фосфатидилсерина на поверхность мембран эритроцитов |
AU2022376537A1 (en) * | 2021-10-29 | 2024-05-16 | Sigilon Therapeutics, Inc. | Compositions for cell-based therapies and related methods |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
WO2023192362A1 (en) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Methods of treating a subject for myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) and compositions for use in the same |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
JPH06505486A (ja) | 1991-02-07 | 1994-06-23 | モレキュメティクス,リミティド | βターンおよびβバルジのコンフォメーション的に制限された模倣物およびそれらを含有するペプチド |
US5475085A (en) | 1991-02-07 | 1995-12-12 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
EP0667786B1 (en) | 1992-08-27 | 2004-01-21 | Deakin Research Limited | Retro-, inverso-, and retro-inverso synthetic peptide analogues |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
EP0706564A1 (en) * | 1993-06-30 | 1996-04-17 | Rijksuniversiteit Leiden | Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods |
US5597457A (en) | 1995-01-23 | 1997-01-28 | The Regents Of The University Of California | System and method for forming synthetic protein crystals to determine the conformational structure by crystallography |
US5840833A (en) | 1995-10-27 | 1998-11-24 | Molecumetics, Ltd | Alpha-helix mimetics and methods relating thereto |
US5929237A (en) | 1995-10-27 | 1999-07-27 | Molecumetics Ltd. | Reverse-turn mimetics and methods relating thereto |
GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
CA2276091A1 (en) * | 1996-12-27 | 1998-07-09 | Mochida Pharmaceutical Co., Ltd. | Cell membrane-directed drugs |
US6093573A (en) | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
CA2331789C (en) * | 1998-07-13 | 2013-09-10 | Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
EP1105523A4 (en) | 1998-08-13 | 2002-09-25 | Wyeth Corp | ESCHERICHIA COLI GDP-FUCOSE SYNTHETASE CRYSTALLINE STRUCTURE AND METHODS OF USE THEREOF |
JP2002523057A (ja) | 1998-08-25 | 2002-07-30 | ザ スクリップス リサーチ インスティテュート | タンパク質の機能を予測するための方法およびシステム |
US6801860B1 (en) | 1999-02-15 | 2004-10-05 | Genetics Institute, Llc | Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
JP2002003407A (ja) * | 2000-06-20 | 2002-01-09 | Medei Sci Puraningu:Kk | ハイドロキシアパタイトカルシウム指向性薬物輸送担体 |
US8275595B2 (en) | 2001-08-14 | 2012-09-25 | Dana-Farber Cancer Institute, Inc. | Computer-based methods of designing molecules |
AU2003298786A1 (en) * | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
BRPI0409497A (pt) * | 2003-04-18 | 2006-05-02 | Novartis Ag | métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite |
KR101191779B1 (ko) * | 2003-06-19 | 2013-01-14 | 맥시겐 홀딩스 엘티디 | 인자 ⅶ 또는 ⅶ에이 지엘에이 도메인 변종들 |
EP1744734A2 (en) | 2004-02-20 | 2007-01-24 | Novo Nordisk A/S | Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds |
US7511016B2 (en) * | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
ATE469216T1 (de) * | 2004-08-17 | 2010-06-15 | Csl Behring Gmbh | Modifizierte vitamin-k-abhängige polypeptide |
CN104277117A (zh) | 2005-01-24 | 2015-01-14 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的Fc融合构建体及其治疗用途 |
WO2006096515A2 (en) | 2005-03-04 | 2006-09-14 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
EP1951277A2 (en) | 2005-10-14 | 2008-08-06 | Biorexis Pharmaceutical Corporation | Natriuretic peptide modified transferrin fusion proteins |
US7624557B2 (en) * | 2006-05-02 | 2009-12-01 | Box Partition Technologies, Inc. | Assembling machine with continuous periodic assembly motion |
AU2008239586B2 (en) | 2007-04-13 | 2013-09-26 | Catalyst Biosciences, Inc. | Modified factor VII polypetides and uses thereof |
KR100968839B1 (ko) * | 2008-02-25 | 2010-07-09 | 경북대학교 산학협력단 | 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도 |
WO2010006136A2 (en) | 2008-07-09 | 2010-01-14 | Mayo Foundation For Medical Education And Research | Adenovirus targeting |
WO2010018847A1 (ja) * | 2008-08-13 | 2010-02-18 | 協和発酵キリン株式会社 | 遺伝子組換えプロテインs組成物 |
US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8283167B2 (en) | 2009-02-11 | 2012-10-09 | Clear Vascular Inc. | Preparation of annexin derivatives |
WO2010151736A1 (en) | 2009-06-25 | 2010-12-29 | The University Of North Carolina At Chapel Hill | Chimeric factor vii molecules |
US20140004601A1 (en) | 2010-12-20 | 2014-01-02 | Agency For Science, Technology And Research | Method of purifying exosomes |
WO2012120130A1 (en) * | 2011-03-09 | 2012-09-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods to characterize patients suffering from hemolysis |
PT2734538T (pt) | 2011-07-18 | 2018-08-02 | Iba Gmbh | Processo para corar, de forma reversível, uma célula-alvo |
AU2013243947A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
WO2014018535A1 (en) | 2012-07-25 | 2014-01-30 | Salk Institute For Biological Studies | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine |
US9406314B1 (en) | 2012-10-04 | 2016-08-02 | Magnecomp Corporation | Assembly of DSA suspensions using microactuators with partially cured adhesive, and DSA suspensions having PZTs with wrap-around electrodes |
ES2756532T3 (es) | 2013-03-15 | 2020-04-27 | Gladiator Biosciences Inc | Dominios de Gla como agentes de direccionamiento |
CA2985369A1 (en) | 2015-05-14 | 2016-11-17 | J.R. Simplot Company | Potato cultivar v11 |
WO2017118764A1 (en) | 2016-01-07 | 2017-07-13 | Thomas Brocker | Novel approaches for the in vivo and in vitro visualization of dying cells |
CN111051500A (zh) | 2017-09-05 | 2020-04-21 | 角斗士生物科学公司 | 有效载荷递送至干细胞 |
-
2014
- 2014-03-13 ES ES14770639T patent/ES2756532T3/es active Active
- 2014-03-13 HR HRP20230632TT patent/HRP20230632T1/hr unknown
- 2014-03-13 MX MX2015011409A patent/MX2015011409A/es unknown
- 2014-03-13 PL PL19160280.4T patent/PL3524617T3/pl unknown
- 2014-03-13 PE PE2015001913A patent/PE20152020A1/es unknown
- 2014-03-13 FI FIEP19160280.4T patent/FI3524617T3/fi active
- 2014-03-13 PL PL19160282.0T patent/PL3524618T3/pl unknown
- 2014-03-13 AU AU2014233885A patent/AU2014233885B2/en active Active
- 2014-03-13 EP EP14769812.0A patent/EP2970442B1/en active Active
- 2014-03-13 JP JP2016502083A patent/JP6595977B2/ja active Active
- 2014-03-13 CN CN201480026243.0A patent/CN105164152B/zh active Active
- 2014-03-13 PL PL14770639T patent/PL2970429T3/pl unknown
- 2014-03-13 FI FIEP19160282.0T patent/FI3524618T3/fi active
- 2014-03-13 RU RU2015144097A patent/RU2705786C2/ru active
- 2014-03-13 HR HRP20230527TT patent/HRP20230527T1/hr unknown
- 2014-03-13 SG SG11201506880WA patent/SG11201506880WA/en unknown
- 2014-03-13 RU RU2015144107A patent/RU2711091C2/ru active
- 2014-03-13 DK DK19160280.4T patent/DK3524617T3/da active
- 2014-03-13 CN CN201480013636.8A patent/CN105008397B/zh active Active
- 2014-03-13 DK DK14770639T patent/DK2970429T3/da active
- 2014-03-13 EP EP19160280.4A patent/EP3524617B1/en active Active
- 2014-03-13 WO PCT/US2014/026237 patent/WO2014151683A1/en active Application Filing
- 2014-03-13 BR BR112015021866A patent/BR112015021866A2/pt active Search and Examination
- 2014-03-13 SG SG11201506307XA patent/SG11201506307XA/en unknown
- 2014-03-13 DK DK19160282.0T patent/DK3524618T3/da active
- 2014-03-13 MX MX2015011873A patent/MX2015011873A/es unknown
- 2014-03-13 ES ES19160282T patent/ES2945994T3/es active Active
- 2014-03-13 PT PT191602804T patent/PT3524617T/pt unknown
- 2014-03-13 DK DK14769812.0T patent/DK2970442T3/da active
- 2014-03-13 EP EP14770639.4A patent/EP2970429B1/en active Active
- 2014-03-13 ES ES14769812T patent/ES2728863T3/es active Active
- 2014-03-13 MY MYPI2015703136A patent/MY176901A/en unknown
- 2014-03-13 EP EP19160282.0A patent/EP3524618B1/en active Active
- 2014-03-13 RU RU2019143609A patent/RU2731507C1/ru active
- 2014-03-13 US US14/772,971 patent/US10894075B2/en active Active
- 2014-03-13 AU AU2014236990A patent/AU2014236990B2/en active Active
- 2014-03-13 PE PE2015001939A patent/PE20152005A1/es active IP Right Grant
- 2014-03-13 SG SG10201913166SA patent/SG10201913166SA/en unknown
- 2014-03-13 PT PT191602820T patent/PT3524618T/pt unknown
- 2014-03-13 JP JP2016502002A patent/JP6471385B2/ja active Active
- 2014-03-13 EP EP22184982.1A patent/EP4174082A1/en active Pending
- 2014-03-13 ES ES19160280T patent/ES2945160T3/es active Active
- 2014-03-13 US US14/773,068 patent/US9694048B2/en active Active
- 2014-03-13 CA CA2905986A patent/CA2905986A1/en active Pending
- 2014-03-13 CA CA3128999A patent/CA3128999C/en active Active
- 2014-03-13 HU HUE19160280A patent/HUE062055T2/hu unknown
- 2014-03-13 MY MYPI2015703057A patent/MY193211A/en unknown
- 2014-03-13 BR BR112015021869A patent/BR112015021869A2/pt active Search and Examination
- 2014-03-13 HU HUE19160282A patent/HUE062021T2/hu unknown
- 2014-03-13 CA CA2905972A patent/CA2905972C/en active Active
- 2014-03-13 WO PCT/US2014/025940 patent/WO2014151535A1/en active Application Filing
-
2015
- 2015-08-12 IL IL24053015A patent/IL240530B/en active IP Right Grant
- 2015-08-26 IL IL240841A patent/IL240841B/en active IP Right Grant
- 2015-09-02 MX MX2021009450A patent/MX2021009450A/es unknown
- 2015-09-13 SA SA515361061A patent/SA515361061B1/ar unknown
- 2015-10-14 ZA ZA2015/07670A patent/ZA201507670B/en unknown
- 2015-10-14 ZA ZA2015/07674A patent/ZA201507674B/en unknown
-
2016
- 2016-03-18 HK HK16103167.3A patent/HK1215263A1/zh unknown
- 2016-04-25 HK HK16104677.4A patent/HK1216649A1/zh unknown
-
2017
- 2017-06-23 US US15/631,937 patent/US20170296624A1/en not_active Abandoned
-
2018
- 2018-10-25 US US16/170,131 patent/US10925926B2/en active Active
- 2018-12-27 JP JP2018244479A patent/JP6812403B2/ja active Active
-
2019
- 2019-09-27 JP JP2019176325A patent/JP2020015752A/ja not_active Withdrawn
- 2019-10-31 IL IL270353A patent/IL270353B2/en unknown
-
2020
- 2020-09-25 US US17/032,162 patent/US20210015900A1/en active Pending
- 2020-12-18 US US17/126,282 patent/US20210113657A1/en active Pending
-
2023
- 2023-06-02 CY CY20231100262T patent/CY1126074T1/el unknown
- 2023-07-04 CY CY20231100311T patent/CY1126072T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230632T1 (hr) | Gla domene kao terapijska sredstva | |
ES2654681T3 (es) | Anticuerpos biespecíficos anti-TNF-anti-IL-17 | |
HRP20190970T1 (hr) | Polipeptidi koji sadrže neglikozilirani fc | |
JP2016513463A5 (ja) | 治療剤としてのGlaドメイン | |
HRP20191865T1 (hr) | Novi heterodimerni proteini | |
JP2017163973A5 (hr) | ||
HRP20161141T1 (hr) | Anti-il-23 protutijela | |
HRP20191835T1 (hr) | Protutijela anti-il-36r | |
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
RU2019127861A (ru) | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn | |
JP2018515096A5 (hr) | ||
HRP20150937T1 (hr) | Pentaspecifiäśno protutijelo | |
HRP20161531T1 (hr) | Fc fuzijski proteini koji sadrže nove linkere ili aranžmane | |
HRP20181047T1 (hr) | Protutijela protiv kemokina pan-elr+ cxc | |
HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
JP2011530309A5 (hr) | ||
HRP20170468T1 (hr) | Bispecifična protutijela protiv baff i protiv il-17 | |
HRP20180155T1 (hr) | Novo protutijelo protiv ljudskog ngf | |
JP2016510736A5 (hr) | ||
IN2014DN07399A (hr) | ||
HRP20200404T1 (hr) | Epitopi proteina f respiratornog sincijalnog virusa | |
IN2014DN05805A (hr) | ||
HRP20210123T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti | |
ZA202104213B (en) | Antibodies that neutralize hepatitis b virus and uses thereof |